PDF(Pubmed)
Abstract：
Background: Tirzepatide-a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist-is used to treat type 2 diabetes. However, the efficacy and safety of tirzepatide in patients undergoing hemodialysis remain unclear. Methods: We conducted a single-center retrospective study of patients with type 2 diabetes undergoing hemodialysis who were transitioned from dulaglutide to tirzepatide. We continuously monitored glucose levels in patients undergoing hemodialysis before and after switching from dulaglutide to tirzepatide. Results: Fourteen patients (mean age: 61.9 ± 9.9 years, male: female = 11:3) were included in this study. After switching to tirzepatide, time in range increased to 50.8% from 42.7% (p = 0.02), time above range decreased to 37.8% from 48.4% (p = 0.02), and mean glucose levels decreased to 137.4 mg/dL from 156.6 mg/dL (p = 0.006). In contrast, there was no significant difference in time below range before and after tirzepatide administration (11.3% and 8.9%) (p = 0.75). Three patients experienced dyspepsia (21.4%), and one patient experienced nausea (7.1%); however, no critical adverse events were reported. Conclusion: Transitioning from dulaglutide to tirzepatide improved glycemic control without increasing hypoglycemia in patients undergoing hemodialysis for type 2 diabetes.
摘要：
背景：Tirzepatide是一种双重葡萄糖依赖性促胰岛素分泌肽和胰高血糖素样肽-1受体激动剂，用于治疗2型糖尿病。然而,在接受血液透析的患者中,替瑞哌肽的疗效和安全性尚不清楚.方法：我们对接受血液透析的2型糖尿病患者进行了一项单中心回顾性研究，这些患者从杜拉鲁肽过渡到了替利西帕肽。我们连续监测血液透析患者在从杜拉鲁肽转换为替拉肽之前和之后的血糖水平。结果：14例患者（平均年龄：61.9±9.9岁，男性：女性=11：3）纳入本研究。改用替利平肽后,范围内的时间从42.7%增加到50.8%(p=0.02)，高于范围的时间从48.4%降至37.8%(p=0.02)，平均葡萄糖水平从156.6mg/dL降至137.4mg/dL（p=0.006）。相比之下,在给药之前和之后,低于范围的时间没有显著差异(11.3%和8.9%)(p=0.75).3例患者出现消化不良（21.4%），一名患者出现恶心(7.1%)；然而，未报告严重不良事件.结论：在接受2型糖尿病血液透析的患者中，从杜拉鲁肽过渡到替拉肽可以改善血糖控制，而不会增加低血糖。
